Outlook Therapeutics (FRA:41O) Debt-to-Equity : -0.62 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Debt-to-Equity?

Outlook Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €29.41 Mil. Outlook Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.22 Mil. Outlook Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €-48.03 Mil. Outlook Therapeutics's debt to equity for the quarter that ended in Dec. 2024 was -0.62.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Outlook Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:41O' s Debt-to-Equity Range Over the Past 10 Years
Min: -11.03 Med: -0.59 Max: 5.91
Current: -0.62

During the past 11 years, the highest Debt-to-Equity Ratio of Outlook Therapeutics was 5.91. The lowest was -11.03. And the median was -0.59.

FRA:41O's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:41O: -0.62

Outlook Therapeutics Debt-to-Equity Historical Data

The historical data trend for Outlook Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Debt-to-Equity Chart

Outlook Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Debt-to-Equity

Get a 7-Day Free Trial

3.11

2.58

1.25

-2.46

-0.41

Outlook Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															-1.50	-0.33	-0.39	-0.41	-0.62

Competitive Comparison of Outlook Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Outlook Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Outlook Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Outlook Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Outlook Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(26.571	+	0.223)	/	-65.842
	=	-0.41

Outlook Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(29.411	+	0.223)	/	-48.027
	=	-0.62

Outlook Therapeutics (FRA:41O) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Outlook Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

OTLK:USA

Address

111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Outlook Therapeutics Headlines

No Headlines